CD44 and breast neoplasm: Given that increased stem cell biomarker expression was observed in high NOS2 expressing ER- breast tumors [7], we measured CSC biomarker expressions (ALDH1A1, OCT4, CXCR4, CD133, CD117, CD44 and NANOG) in the control and DETANO treated MCF10A cells.